Wu, Youming
Tong, Yongqing
Zhang, Haitao
Li, Yun
Zhu, Xu
Li, Ming
Qiu, Lili
Liu, Wenlan
Mei, Siqing
Mao, Yu
Cao, Yanhua
Su, Caiyan
Yu, Wentao
Wang, Junli
Wang, Taizhong
Zhu, Zhongyuan
Yu, De-Hua
Article History
Received: 28 April 2024
Accepted: 16 July 2024
First Online: 30 July 2024
Declarations
:
: The studies involving human participants were reviewed and approved by Renmin Hospital of Wuhan University, the Second People’s Hospital of Shenzhen, and the Second Affiliated Hospital of Hainan Medical University. They were in accordance in with Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from each participant.
: Not applicable.
: The authors declare no competing interests.
: CRC: Colorectal cancer,FIT: Fecal immunochemical testing,mtsDNA: multi target stool DNA,CSCO: Chinese Society of Clinical Oncology,FOBT: Fecal occult blood testing,ESD: Post-Endoscopic Submucosal Dissection,ASIR: Age-standardized incidence rate,Ct: Cycle threshold,NGS: Next-Generation Sequencing,ctDNA: circulating tumor DNA,qMSP: Quantitative methylation-specific PCR,BCAT1: Branched-chain amino acid transaminase 1,SDC2: Syndecan-2,ROC: Receiver operating characteristic.
: Not applicable.